NCT02258451
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Radiation Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with inflammatory breast cancer (IBC); Subjects with known or history of brain metastases or leptomeningeal disease- see trial for details
https://ClinicalTrials.gov/show/NCT02258451